MedTrace Logo

PET Scan Imaging of Beta Cell Mass

NCT00771576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-07-18

No results posted yet for this study

Summary

The investigators hypothesize that PET scans will be able to differentiate between normal, reduced or increased BCM in human subjects. Subjects with normal BCM will be recruited from among normal weight nondiabetic people with plasma insulin levels within the normal range. Subjects with predicted reduced BCM will be recruited from among patients with T1DM who have with low or not measurable insulin levels. If results from the nondiabetic subjects and the subjects with T1DM are found to differ significantly, subjects with increased BCM will be recruited from among patients with hyperinsulinemia including those with obesity and the metabolic syndrome. PET scan measurements of the pancreas will be obtained and compared in people predicted, on the basis of biochemical testing, to have normal or reduced, or increased BCM.

Conditions

Sponsors & Collaborators

Principal Investigators

  • PAUL E HARRIS, Ph.D. · Columbia University

  • Robin S Goland, M.D. · Columbia University

  • Ronald Van Heertum, M.D. · Columbia University

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-09-30
Completion
2012-06-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771576 on ClinicalTrials.gov